

Abacavir

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
 Oral > Solid: 300 mg tablet (as sulfate)

Indications

Human immunodeficiency virus disease
 without mention of associated disease or
 condition, clinical stage unspecified

Didanosine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
 Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered
 powder for oral solution; 250 mg buffered powder for oral solution
 Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered
 chewable dispersible tablet; 100 mg buffered chewable dispersible tablet;
 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable
 dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg
 unbuffered enteric coated capsule; 250 mg unbuffered enteric coated
 capsule; 400 mg unbuffered enteric coated capsule

Indications

Human immunodeficiency virus disease
 without mention of associated disease or
 condition, clinical stage unspecified

Emtricitabine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
 Oral > Liquid: 10 mg per mL
 Oral > Solid: 200 mg

Indications

Human immunodeficiency virus disease
 without mention of associated disease or
 condition, clinical stage unspecified

Lamivudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
 Oral > Liquid: 50 mg per 5 mL
 Oral > Solid: 150 mg tablet

Indications

Human immunodeficiency virus disease
 without mention of associated disease or
 condition, clinical stage unspecified

Stavudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
 Oral > Liquid: 5 mg per 5 mL powder for oral solution
 Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

Human immunodeficiency virus disease
 without mention of associated disease or
 condition, clinical stage unspecified

Tenofovir disoproxil fumarate

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Zidovudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion
Oral > Liquid: 50 mg per 5 mL
Oral > Solid > tablet: 300 mg
Oral > Solid > capsule: 250 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified